Rubella Vaccine Market By End User, And Region (2017 To 2022)
The market is dominated by companies like Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotec
(EMAILWIRE.COM, April 19, 2018 ) The global Rubella Vaccine (Human Diploid Cell) market is anticipated to grow at XX % CAGR from 2017 to 2022 and it is estimated that the global market was valued at USD XX billion in 2017 and is expected to reach USD XX billion by 2022.
Browse full report @ https://marketdataforecast.com/market-reports/rubella-vaccine-market-6397/
Rubella is an acute, viral, and contagious infection, which has a mild effect on children and is caused by the transmission of airborne droplets of infected people through sneezing or coughing. However, pregnant women suffering from rubella have to face severe consequences, as the viral infection results in death or congenital defects known as congenital rubella syndrome (CRS). Rubella vaccine has gained traction over the years as the disease is preventable only through vaccination and no other specific treatments exist for it.
Get free sample report @ https://marketdataforecast.com/market-reports/rubella-vaccine-market-6397/request-sample
The major factors that fuel the growth of the market are an increase in the incidence of rubella infection globally Approximately 100,000 infants are affected by rubella annually, thus increasing the government focus on rubella vaccination, which further propels the market growth. However, inherent disadvantages of using human diploid cell technology for constructing rubella vaccines such as high selectivity and insufficient yield, restrain the growth of the market. Conversely, ongoing R&D activities for the advancement of rubella vaccines are expected to offer lucrative opportunities for the growth of the market.
Buy now @ https://marketdataforecast.com/cart/buy-now/rubella-vaccine-market-6397/
The global Rubella Vaccine market is segmented on the basis of End User. On the basis of End User, the market is segmented into Pediatric Rubella Vaccine, Adult Rubella Vaccine, and Traveler Rubella Vaccine.
On the basis of geography, the Rubella Vaccine market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the Rubella Vaccine market followed by Europe and Asia Pacific. Asia Pacific is expected to witness the highest CAGR in the coming years.
The market is dominated by companies like Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).
About Market Data Forecast™
Market Data Forecast is a market research firm offering syndicated research, consults and industry newsletters across various domains & verticals. With a well-established in-house team of experts from diverse fields and outsource research network across 100+ countries, we are the sole research providers for the majority of Fortune 500 companies. Along with the standards of reports being on par excellence, our unique services like free customization, analyst support for the period of six months post to the purchase will be the flag bearers and differentiates us from the rest. Our experience and in-depth understanding of various business environments will be a support to you and your organization in making well-informed decisions
Browse full report @ https://marketdataforecast.com/market-reports/rubella-vaccine-market-6397/
Rubella is an acute, viral, and contagious infection, which has a mild effect on children and is caused by the transmission of airborne droplets of infected people through sneezing or coughing. However, pregnant women suffering from rubella have to face severe consequences, as the viral infection results in death or congenital defects known as congenital rubella syndrome (CRS). Rubella vaccine has gained traction over the years as the disease is preventable only through vaccination and no other specific treatments exist for it.
Get free sample report @ https://marketdataforecast.com/market-reports/rubella-vaccine-market-6397/request-sample
The major factors that fuel the growth of the market are an increase in the incidence of rubella infection globally Approximately 100,000 infants are affected by rubella annually, thus increasing the government focus on rubella vaccination, which further propels the market growth. However, inherent disadvantages of using human diploid cell technology for constructing rubella vaccines such as high selectivity and insufficient yield, restrain the growth of the market. Conversely, ongoing R&D activities for the advancement of rubella vaccines are expected to offer lucrative opportunities for the growth of the market.
Buy now @ https://marketdataforecast.com/cart/buy-now/rubella-vaccine-market-6397/
The global Rubella Vaccine market is segmented on the basis of End User. On the basis of End User, the market is segmented into Pediatric Rubella Vaccine, Adult Rubella Vaccine, and Traveler Rubella Vaccine.
On the basis of geography, the Rubella Vaccine market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the Rubella Vaccine market followed by Europe and Asia Pacific. Asia Pacific is expected to witness the highest CAGR in the coming years.
The market is dominated by companies like Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).
About Market Data Forecast™
Market Data Forecast is a market research firm offering syndicated research, consults and industry newsletters across various domains & verticals. With a well-established in-house team of experts from diverse fields and outsource research network across 100+ countries, we are the sole research providers for the majority of Fortune 500 companies. Along with the standards of reports being on par excellence, our unique services like free customization, analyst support for the period of six months post to the purchase will be the flag bearers and differentiates us from the rest. Our experience and in-depth understanding of various business environments will be a support to you and your organization in making well-informed decisions
Contact Information:
Market Data Forecast.
Abhishek Shukla
Tel: +1-888-702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast.
Abhishek Shukla
Tel: +1-888-702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results